Person: ŞADIRVAN OĞUZKAYA, YAĞMUR HAZAL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ŞADIRVAN OĞUZKAYA
First Name
YAĞMUR HAZAL
Name
3 results
Search Results
Now showing 1 - 3 of 3
Publication Recombinase activating gene defects, phenotypic diversity(Wiley, 2023-12-01) Yorgun, M.; Aydıner, E. Karakoç; Özen, A.; Barıs, S.; Oğuzkaya, Y. Şadırvan; ŞADIRVAN OĞUZKAYA, YAĞMUR HAZAL; Çekiç, Şükrü; ÇEKİÇ, ŞÜKRÜ; Karalı, Zuhal; KARALI, ZUHAL; Kılıç, Sara Şebnem; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Tıp Fakültesi; 0000-0002-9574-1842; 0000-0002-4730-9422Publication The evaluation of local and systemic reactions to subcutaneous house dust mite allergen immunotherapy(Galenos Publ House, 2022-06-15) Canitez, Yakup; CANITEZ, YAKUP; Karali, Zuhal; KARALI, ZUHAL; ÇEKİÇ, ŞÜKRÜ; SAPAN, NİHAT; Şadırvan, Yağmur Hazal; ŞADIRVAN OĞUZKAYA, YAĞMUR HAZAL; Tıp Fakültesi; Pediatri Ana Bilim Dalı; L-1933-2017Objective: Allergen -specific immunotherapy is an effective treatment method that enables the development of immunotolerance against allergens in allergic rhinitis, asthma, and venom allergy. This study investigated the local and systemic reactions during subcutaneous house dust mite allergen immunotherapy. Methods: Injection -related local and systemic reactions of 45 patients who received subcutaneous mite immunotherapy were evaluated retrospectively. Results: Forty-five children, 15 (33.3%) females and 30 (66.4%) male were included in the study. A total of 582 injections were administered. A local reaction was observed in 23 (3.94%) of all injections and the systemic reaction was observed in only 1 (0.17%) injection. Sixteen (37.7%) of the children had local reactions during the immunotherapy process and 1 (2.2%) had a systemic reaction. Conclusion: Although subcutaneous mite immunotherapy is a safe treatment, it should only be applied in centers with appropriate emergency equipment and trained healthcare professionals due to possible systemic reactions.Publication Compliance with follow-up and adherence to Immunoglobulin Treatment in patients with primary immunodeficiency during The Pandemic(Springer/Plenum Publishers, 2022-04-01) Karalı, Zühal; Çekiç, Şükrü; Oğuzkaya, Yağmur; Kılıç, Sara Şebnem; KARALI, ZUHAL; ÇEKİÇ, ŞÜKRÜ; ŞADIRVAN OĞUZKAYA, YAĞMUR HAZAL; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Tıp Fakültesi; 0000-0002-9574-1842; 0000-0001-8571-2581; L-1933-2017; AAH-1658-2021; CZC-9168-2022; DKN-7999-2022